

Abstract

5 The invention provides new methods for treating certain disorders resulting from
neurodegeneration and for treating depression which comprise administration of NR2B
subunit selective NMDA antagonists. The disorders that can be treating by the invention
include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin
poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and
10 depression.